Preferred Label : Anti-CLL1-PBD ADC DCLL9718S;
NCIt synonyms : TDC DCLL9718S; Anti-CLL1/PBD ADC DCLL9718S; THIOMAB ADC DCLL9718S; Anti-CLL-1 ADC DCLL9718S; ADC DCLL9718S;
CISMeF acronym : ADC DCLL9718S;
NCIt definition : An antibody-drug conjugate (ADC) consisting of MCLL0517A , an anti-C-type lectin-like
molecule-1 (CLL-1; CLL1; C-type lectin domain family 12 member A; CLEC12A) humanized
immunoglobulin G1 (IgG1) monoclonal antibody, conjugated, via a cleavable disulfide
linker, to two cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine
(PBD) dimers, with potential antineoplastic activity. Upon administration of anti-CLL1-PBD
ADC DCLL9718S, the antibody moiety targets the cell surface tumor-associated antigen
(TAA) CLL1. Upon antibody/antigen binding, internalization, and lysosome uptake, the
cytotoxic PBD moiety is released. The imine groups of the PBD moiety covalently bind
to the N2 positions of guanines on opposite strands in the minor groove of DNA. This
induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest,
induces cell death, and inhibits the proliferation of CLL1-overexpressing tumor cells.
CLL1, a transmembrane glycoprotein and member of the C-type lectin/C-type lectin-like
domain (CTL/CTLD) superfamily, is overexpressed in leukemic stem cells (LSCs) while
absent on normal hematopoietic stem cells (HSCs). It plays an important role in disease
progression and relapse of myeloid malignancies.;
Molecule name : DCLL-9718S; RG 6109; DCLL 9718S; RG-6109;
NCI Metathesaurus CUI : CL1662984;
Origin ID : C180614;
UMLS CUI : C5544819;
Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
